IRIS
MOCCIA, MARCELLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 9.446
NA - Nord America 7.730
EU - Europa 6.096
SA - Sud America 1.153
AF - Africa 246
OC - Oceania 19
Continente sconosciuto - Info sul continente non disponibili 5
Totale 24.695
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.389
SG - Singapore 4.035
RU - Federazione Russa 2.604
CN - Cina 1.743
VN - Vietnam 1.652
IT - Italia 1.386
BR - Brasile 888
HK - Hong Kong 809
DE - Germania 515
FR - Francia 337
NL - Olanda 299
IN - India 229
GB - Regno Unito 192
CA - Canada 187
JP - Giappone 183
FI - Finlandia 166
BD - Bangladesh 163
UA - Ucraina 128
IE - Irlanda 110
KR - Corea 107
AR - Argentina 101
MX - Messico 86
CI - Costa d'Avorio 68
ES - Italia 67
IQ - Iraq 66
PH - Filippine 66
SE - Svezia 66
ZA - Sudafrica 65
IR - Iran 51
EC - Ecuador 49
PL - Polonia 49
TH - Thailandia 48
ID - Indonesia 44
AT - Austria 37
CO - Colombia 37
TR - Turchia 33
TW - Taiwan 33
PK - Pakistan 31
SA - Arabia Saudita 27
LT - Lituania 25
MA - Marocco 21
VE - Venezuela 21
BE - Belgio 18
CZ - Repubblica Ceca 18
CL - Cile 17
EG - Egitto 17
JM - Giamaica 17
NP - Nepal 17
KE - Kenya 16
PE - Perù 16
JO - Giordania 14
MY - Malesia 13
BG - Bulgaria 12
UZ - Uzbekistan 12
DZ - Algeria 11
TN - Tunisia 11
AE - Emirati Arabi Uniti 10
AU - Australia 10
PY - Paraguay 10
IL - Israele 9
NI - Nicaragua 8
CR - Costa Rica 7
MK - Macedonia 7
UY - Uruguay 7
BO - Bolivia 6
CH - Svizzera 6
LB - Libano 6
MN - Mongolia 6
NG - Nigeria 6
NZ - Nuova Zelanda 6
PT - Portogallo 6
AL - Albania 5
AM - Armenia 5
DO - Repubblica Dominicana 5
GR - Grecia 5
HN - Honduras 5
KZ - Kazakistan 5
OM - Oman 5
RS - Serbia 5
AZ - Azerbaigian 4
BB - Barbados 4
ET - Etiopia 4
HR - Croazia 4
RO - Romania 4
SN - Senegal 4
XK - ???statistics.table.value.countryCode.XK??? 4
BH - Bahrain 3
BY - Bielorussia 3
CG - Congo 3
CU - Cuba 3
DM - Dominica 3
GA - Gabon 3
GE - Georgia 3
GT - Guatemala 3
HU - Ungheria 3
MD - Moldavia 3
PA - Panama 3
QA - Qatar 3
SK - Slovacchia (Repubblica Slovacca) 3
SY - Repubblica araba siriana 3
Totale 24.642
Salva come PNG Salva come JPEG
Città #
Singapore 1.942
San Jose 1.314
Hong Kong 777
Ashburn 743
Moscow 743
Chandler 605
Ho Chi Minh City 458
Hefei 455
Beijing 419
Hanoi 378
Santa Clara 376
Naples 305
Amsterdam 232
Los Angeles 211
Lauterbourg 203
Millbury 200
The Dalles 175
Tokyo 167
Des Moines 133
New York 128
Lawrence 118
Council Bluffs 111
Munich 111
Dallas 104
Redondo Beach 103
Buffalo 87
São Paulo 85
Boston 83
Milan 80
Napoli 78
Seoul 77
Houston 71
Nanjing 71
Haiphong 70
Da Nang 67
Frankfurt am Main 61
Helsinki 60
Princeton 57
Rome 57
Seattle 54
Orem 52
Chicago 49
Wilmington 49
Montreal 48
Ottawa 45
Dong Ket 44
Denver 41
Dublin 41
Norwalk 40
Warsaw 40
Toronto 37
Falkenstein 35
Columbus 34
Krefeld 34
Mexico City 34
Chennai 33
London 33
Turku 32
Atlanta 31
Brooklyn 31
Nuremberg 30
Rio de Janeiro 30
Stockholm 30
Phoenix 29
Johannesburg 28
Lappeenranta 26
San Francisco 26
Tianjin 25
Baghdad 23
Hải Dương 23
Vienna 23
Pune 22
Bangkok 20
Manchester 20
Belo Horizonte 19
Biên Hòa 19
Poplar 19
Quito 17
Can Tho 16
Paris 16
Rottweil 15
Ankara 14
Brasília 14
Changsha 14
Dearborn 14
Hebei 14
Jacksonville 14
New Delhi 14
Porto Alegre 14
Thái Nguyên 14
Washington 14
Amman 13
Boardman 13
Curitiba 13
Guayaquil 13
Mumbai 13
Nairobi 13
Nanchang 13
Shanghai 13
Shenzhen 13
Totale 13.085
Salva come PNG Salva come JPEG
Nome #
AQP4-MOG Double-Positive Neuromyelitis Optica Spectrum Disorder: Case Report with Central and Peripheral Nervous System Involvement and Review of Literature 280
Quality of Life and Cognitive function in pediatric and young adults multiple sclerosis: a cross-sectional study 234
Uric acid: a potential biomarker of multiple sclerosis and of its disability 209
Speech discrimination is impaired in parkinsonian patients: Expanding the audiologic findings of Parkinson's disease 190
The ocrelizumab wearing-off phenomenon is associated with reduced immunomodulatory response and increased neuroaxonal damage in multiple sclerosis 185
ChatGPT vs. neurologists: a cross-sectional study investigating preference, satisfaction ratings and perceived empathy in responses among people living with multiple sclerosis 184
MRI features suggestive of gadolinium retention do not correlate with Expanded Disability Status Scale worsening in Multiple Sclerosis 182
Incidence and Prevalence of Dementia: A 2015-2020 Population-Based Study in the Campania Region of Italy 170
2D linear measures of ventricular enlargement may be relevant markers of brain atrophy and long-term disability progression in multiple sclerosis 169
The effect of air pollution on COVID-19 severity in a sample of patients with multiple sclerosis 166
White matter changes and the development of motor phenotypes in de novo Parkinson's Disease 166
Cognitive impairment at diagnosis predicts 10-year multiple sclerosis progression 165
Prognostic Markers of Ocrelizumab Effectiveness in Multiple Sclerosis: A Real World Observational Multicenter Study 163
Coenzyme Q10 supplementation reduces peripheral oxidative stress and inflammation in interferon-β1a-treated multiple sclerosis 161
JCV antibodies index on natalizumab treatment: fluctuations and seroconversion. 159
Validation of the Italian version of the Multiple Sclerosis Intimacy and Sexuality Questionnaire-19 158
Peripapillary Vessel Density as Early Biomarker in Multiple Sclerosis 156
Quality of Life Changes in Early-Onset Multiple Sclerosis: A 4-Year Follow-Up Study 155
The Heterogeneity of Early Parkinson?s Disease: A Cluster Analysis on Newly Diagnosed Untreated Patients 155
Serum epidermal growth factor predicts cognitive functions in early, drug-naive Parkinson's disease patients. 153
Gender and non motor fluctuations in Parkinson's disease: A prospective study 153
Early combination of sotrovimab with nirmatrelvir/ritonavir or remdesivir is associated with low rate of persisting SARS CoV-2 infection in immunocompromised outpatients with mild-to-moderate COVID-19: a prospective single-centre study 151
Hypomorphic NOTCH3 mutation in an Italian family with CADASIL features 151
Changes in lymphocytes, neutrophils and immunoglobulins in year-1 cladribine treatment in multiple sclerosis 150
Normative values of the Rao’s Brief Repeatable Battery in an Italian young adolescent population: the influence of age, gender, and education 150
Signs and symptoms of COVID-19 in patients with multiple sclerosis 148
Grey/white matter ratio at diagnosis, and the risk of 10-year multiple sclerosis progression 148
Pediatric-onset Multiple Sclerosis treatment: a multicentre observational study comparing natalizumab with fingolimod 146
Correction to: Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study (Journal of Neurology, (2022), 269, 6, (3301-3307), 10.1007/s00415-022-11009-x) 146
Apathy in untreated, de novo patients with Parkinson's disease: validation study of Apathy Evaluation Scale. 146
How many injections did you miss last month? A simple question to predict interferon β-1a adherence in multiple sclerosis 146
Tango classes in people with Multiple Sclerosis (PwMS): Impact on motor and non-motor functions 145
Are granular osmiophilic material deposits an epiphenomenon in CADASIL? 145
CD4/CD8 ratio during natalizumab treatment in multiple sclerosis patients 145
Presence and progression of non-motor symptoms in relation to uric acid in de novo Parkinson's disease 145
Persistence, adherence, healthcare resource utilisation and costs for interferon Beta in multiple sclerosis: a population-based study in the Campania region (southern Italy) 145
Immunometabolic profiling of patients with multiple sclerosis identifies new biomarkers to predict disease activity during treatment with interferon beta-1a 144
Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study 143
Impulsive-compulsive behaviors in parkin-associated Parkinson disease 143
Quality of life and cognitive function in pediatric and young multiple sclerosis patients: a cross-sectional study 143
Mental Health in Multiple Sclerosis During the COVID-19 Outbreak: A Delicate Balance between Fear of Contagion and Resilience 143
Fertility, pregnancy and childbirth in women with multiple sclerosis: a population-based study from 2018 to 2020 142
Quitting smoking: An early non-motor feature of Parkinson's disease? 142
Cognitive trajectories in multiple sclerosis: a long-term follow-up study 142
Neurofilament light chain and Alzheimer pathology biomarkers in elderly people with multiple sclerosis 141
Uric acid in relapsing–remitting multiple sclerosis: a 2-year longitudinal study 141
Persistence with Botulinum Toxin Treatment for Spasticity Symptoms in Multiple Sclerosis 139
Clinical application of age-derived cut-offs for plasma neurofilament light chain in multiple sclerosis 139
A four-year longitudinal study on restless legs syndrome in Parkinson disease 138
ProspeCtive study to evaluate efficacy, safety and tOlerability of dietary supplemeNT of Curcumin (BCM95) in subjects with Active relapsing MultIple Sclerosis treated with subcutaNeous Interferon beta 1a 44 mcg TIW (CONTAIN): A randomized, controlled trial 138
Being highly sensitive person negatively impacts on cognitive and psychosocial fatigue in multiple sclerosis patients: A cross-sectional, monocenter study 137
Retinal vascular density in multiple sclerosis: a one year follow up 137
Impact of an anti-infective screening and monitoring protocol together with infectious disease consultation in preventing infective adverse events in patients treated with anti-CD20/CD52 agents for multiple sclerosis 136
Multiple Sclerosis in the Campania Region (South Italy): Algorithm Validation and 2015-2017 Prevalence 136
Uric acid relates to dopamine transporter availability in Parkinson's disease 135
Physical Exercise Moderates the Effects of Disability on Depression in People with Multiple Sclerosis during the COVID-19 Outbreak 135
Monocular Diplopia in Idiopathic Intracranial Hypertension: A Case Report and Literature Review 135
Increased endothelin-1 serum levels in patients with multiple sclerosis 134
Sexual dysfunction in multiple sclerosis: The impact of different MSISQ-19 cut-offs on prevalence and associated risk factors 133
COVID-19 pandemic and mental distress in Multiple Sclerosis: implications for clinical management 133
Risk of invasive fungal infections among patients treated with disease modifying treatments for multiple sclerosis: a comprehensive review 133
Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: Two cases and implications for clinical practice 132
Exploring the relation between reserve and fatigue in multiple sclerosis 131
Effect of siponimod on lymphocyte subsets in active secondary progressive multiple sclerosis and clinical implications 130
Brain tissue volumes and relaxation rates in multiple sclerosis: implications for cognitive impairment 130
Healthcare resource utilization and costs for multiple sclerosis management in the Campania region of Italy: Comparison between centre-based and local service healthcare delivery 130
Predictors of Nabiximols (Sativex®) discontinuation over long-term follow-up: a real-life study 130
A retrospective exploratory analysis on cardiovascular risk and cognitive dysfunction in multiple sclerosis 130
Update on infective complications in patients treated with alemtuzumab for multiple sclerosis: review and meta-analysis of real-world and randomized studies 130
Technological interventions in European dementia care: a systematic review of acceptance and attitudes among people living with dementia, caregivers, and healthcare workers 129
Determinants of early working impairments in multiple sclerosis 128
The impact of diagnostic criteria and treatments on the 20-year costs for treating relapsing-remitting multiple sclerosis 128
Interplay Between Cognitive and Bowel/Bladder Function in Multiple Sclerosis 127
MR Imaging Signs of Gadolinium Retention Are Not Associated with Long-Term Motor and Cognitive Outcomes in Multiple Sclerosis 126
COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context 125
Apathy and striatal dopamine transporter levels in de-novo, untreated Parkinson's disease patients 124
Non-motor correlates of smoking habits in de novo Parkinson's disease 124
Ocrelizumab depletes T-lymphocytes more than rituximab in multiple sclerosis 124
Impact of COVID-19 and system recovery in delivering healthcare to people with multiple sclerosis: a population-based Study 123
Biomarkers of Parkinson's disease: recent insights, current challenges, and future prospects 123
SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study 123
Digital Technology in Clinical Trials for Multiple Sclerosis: Systematic Review 122
Clinical clusters and dopaminergic dysfunction in de-novo Parkinson disease 122
Monitoring of safety and effectiveness of cladribine in multiple sclerosis patients over 50 years 121
The EDSS integration with the Brief International Cognitive Assessment for Multiple Sclerosis and orientation tests 121
Global investments in pandemic preparedness and COVID-19: development assistance and domestic spending on health between 1990 and 2026 121
DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France 120
The use of University of Pennsylvania Smell Identification Test in the diagnosis of Parkinson's disease in Italy. 120
Prevalence of SARS-CoV-2 Antibodies in Multiple Sclerosis: The Hidden Part of the Iceberg 120
The independent contribution of brain, spinal cord and gadolinium MRI in treatment decision in multiple sclerosis: A population-based retrospective study 120
Dysphagia assessment in patients with multiple sclerosis - an additional piece to disability burden 119
Ocrelizumab effect on humoral and cellular immunity in multiple sclerosis and its clinical correlates: a 3-year observational study 119
Identifying neuropsychological phenotypes in multiple sclerosis using latent profile analysis 119
Olfactory function and cognition in relapsing–remitting and secondary-progressive multiple sclerosis 119
Relationship between apathy and cognitive dysfunctions in de novo untreated Parkinson's disease: a prospective longitudinal study. 118
Unraveling diagnostic uncertainty in transition phase from relapsing-remitting to secondary progressive multiple sclerosis 118
Epidemiology of multiple sclerosis in the Campania Region (Italy): Derivation and validation of an algorithm to calculate the 2015-2020 incidence 117
Fake news, influencers and health-related professional participation on the Web: A pilot study on a social-network of people with Multiple Sclerosis 117
Utilization of Ocrelizumab within Different Treatment Strategies for Multiple Sclerosis: A 5-Year Population-Based Study 117
Serum epidermal growth factor predicts cognitive functions in early, drug-naive Parkinson's disease patients 116
Totale 14.195
Salva come PNG Salva come JPEG
Categoria #
all - tutte 81.686
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 81.686
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022966 12 2 6 15 17 89 11 33 87 98 180 416
2022/20231.708 184 117 32 117 160 251 166 120 242 192 98 29
2023/20241.100 43 159 133 57 53 113 77 109 24 28 169 135
2024/20256.385 319 359 43 91 197 367 663 436 492 686 2.122 610
2025/202613.370 1.257 1.004 1.364 1.185 2.191 449 1.359 1.121 1.699 974 366 401
2026/2027234 234 0 0 0 0 0 0 0 0 0 0 0
Totale 25.339